SOURCE: CTD Holdings, Inc.

CTD Holdings, Inc. Logo

June 08, 2015 07:00 ET

CTD Holdings Announces Family and Physicians Listening Circle on NPC Treatment

Group Will Advise the Company on Its International Clinical Program

ALACHUA, FL--(Marketwired - June 08, 2015) - CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that distribute and manufacture cyclodextrin-based products, today announced the Family and Physicians Listening Circle, which will serve as an information sharing forum for families, physicians, and CTD's International Clinical Program team working to develop orphan drug designated Trappsol® Cyclo™ for the treatment of Niemann-Pick Type C (NPC), a rare and fatal disease found primarily in children.

Co-Chairs of the Listening Circle are Sue French of the UK, a parent of an NPC affected child, and Dr. Caroline Hastings of the UCSF Benioff Children's Hospital Oakland, a pediatrician and pioneer in the use of cyclodextrins in the treatment of NPC.

"This Listening Circle will provide families with an opportunity to gain an understanding of the science behind cyclodextrins, while giving the families an opportunity to share lessons learned with other treatments and to provide support to and gain support from the process," said Sue French.

Dr. Hastings added, "The Listening Circle is an innovative approach that will allow physicians and families to come together to discuss potential treatment designs and to work as partners with the private sector." Dr. Hastings also is a member of CTD's Scientific Advisory Board.

Also joining the panel as inaugural members are David French, husband of Sue French and father of an affected child, and Dr. Robin Lachmann, of the Charles Dent Metabolic Unit, National Hospital for Neurology and Neurosurgery, London, who has broad experience in treating inherited metabolic disorders like NPC.

Dr. Sharon Hrynkow, also a member of CTD's Scientific Advisory Board, said, "The Listening Circle gives CTD the opportunity to learn from families and those providing care to NPC patients about potential trial design elements, while also serving as a platform to share scientific updates on cyclodextrins and other information. All of us involved expect to listen, learn, and share -- to the benefit of patients and families."

About the Company:
CTD Holdings, Inc. is a family of biotechnology growth companies based on cyclodextrin chemistry. Its individual divisions distribute and manufacture the trademarked Trappsol® and Aquaplex® cyclodextrins, cyclodextrin derivatives, and cyclodextrin complexes for biotechnology and life science companies involved in the research, pharmaceutical, medical device, cosmetics and nutrition markets. Sphingo Biotechnology, Inc. is developing Trappsol® Cyclo™, an orphan drug designated product, for the treatment of Niemann-Pick Type C, a rare and fatal genetic disease in young children. NanoSonic Products, Inc. operates the world's only cGMP pulse drying facility for the production of UltraPure™ cyclodextrin derivatives and pharmaceutical grade Aquaplex® cyclodextrin complexes. CTD, Inc. supplies cyclodextrins to biotechnology and life science researchers around the globe from the world's largest catalog of cyclodextrins. The companies offer a wide variety of cyclodextrin related manufacturing services to worldwide customers, including custom formulation, manufacturing, and commercial scale supply of pharmaceutical grade cyclodextrin complexes. For additional information, visit the Company's websites: and

Safe Harbor Statement:
This press release contains "forward-looking statements" about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the Company's future performance include the Company's ability to obtain additional capital to expand operations as planned, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing food and pharmaceutical grade products. These and other risk factors are described from time to time in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's reports on Forms 10-K and 10-Q. Unless required by law, the Company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Contact Information